> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tonix Lawsuit Triggers Up To 30 Months Of Delay For Generic TONMYA Approval
- URL: https://www.bullished.co/tonix-lawsuit-triggers-up-to-30-months-of-delay-for-generic-tonmya-approval-cf0bf04c/
- Published: 2026-11-13T21:42:08.000Z
- Updated: 2026-11-13T21:42:08.000Z
- Description: Tonix seeks to keep the competing drug’s approval from taking effect until the last asserted patent expires.
- Author: Matteo Parrino
- Tags: SEC Filings, TNXP, Industry: Healthcare

[Tonix Pharmaceuticals](https://www.bullished.co/tag/tnxp/), which sells and develops medicines, sued Friday over a proposed generic version of TONMYA, triggering a pause of [up to 30 months](https://www.sec.gov/Archives/edgar/data/0001430306/000149315226051693/form8-k.htm?ref=bullished.co) in final FDA approval. The company said in its [8-K](https://www.bullished.co/learn/8-k-items-explained/) that the pause remains subject to exceptions and court orders.

## A Fight Through Patent Expiration

Tonix sued Dr. Reddy’s Laboratories, the applicant seeking approval for the competing drug, in the United States District Court for the District of New Jersey. Tonix alleges that the generic application infringes certain patents protecting TONMYA.

The company wants the court to bar approval from taking effect until the last asserted patent expires. That request seeks protection tied to the patents’ expiration, while the statutory pause triggered by the lawsuit has a maximum duration of 30 months.

The dispute concerns TONMYA’s 2.8 mg cyclobenzaprine hydrochloride tablets, which dissolve under the tongue. Tonix [received notice](https://www.sec.gov/Archives/edgar/data/0001430306/000149315226051693/form8-k.htm?ref=bullished.co) of Dr. Reddy’s application on October 1, 2026, a development it had previously made public.

Dr. Reddy’s challenged four patents listed for TONMYA in the FDA’s Orange Book, its reference for approved drugs. Its application included a Paragraph IV certification: the applicant’s position that the patents are invalid, cannot be enforced or would not be infringed by its generic product.

## TONMYA Sales Are At Stake

TONMYA is approved for fibromyalgia in adults and launched on November 17, 2025\. Tonix’s marketed medicines also include the acute migraine treatments Zembrace SymTouch, a sumatriptan injection, and Tosymra, a sumatriptan nasal spray.

Tonix’s annual report for 2025 described about 90 U.S. sales representatives promoting TONMYA. The company reaches physicians and other prescribers through its own and contracted sales teams, national wholesalers and specialty distributors.

The timing of generic entry matters to that commercial business. Tonix identified potential harm to TONMYA sales from generic competition, along with litigation costs and demands on management’s attention, as risks.

Tonix also cautioned that patents could be found invalid, unenforceable or not infringed, and that the FDA could approve Dr. Reddy’s application or other generic applications.

The lawsuit has triggered a temporary approval pause; Tonix’s request for protection through patent expiration remains before the court.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Tonix Pharmaceuticals Holding Corp. (TNXP)](https://www.sec.gov/Archives/edgar/data/0001430306/000149315226051693/form8-k.htm?ref=bullished.co) — SEC EDGAR

### More on Tonix Pharmaceuticals

- [Tonix Has Successor Drugs In Early Development As Analysts Press On TONMYA Patent Protection](https://www.bullished.co/tonix-has-successor-drugs-in-early-development-as-analysts-press-on-tonmya-patent-67a24a25/)
- [Tonix’s TONMYA Sales Rise 37% — But Its Quarterly Loss Reaches $53.3 Million](https://www.bullished.co/tonixs-tonmya-sales-rise-37-but-its-quarterly-loss-reaches-53-3-million-afd51313/)
- [Tonix Estimates TONMYA Net Revenue Of $14.0 Million To $15.0 Million For Third Quarter](https://www.bullished.co/tonix-estimates-tonmya-net-revenue-of-14-0-million-to-15-0-million-for-third-quarter-a50cc25b/)

[All Tonix Pharmaceuticals (TNXP) coverage →](https://www.bullished.co/tag/tnxp/)